“Buzz on the Street” Show: Mydecine Innovations Group (OTC: NLBIF) (CSE: MYCO) to Acquire NeuroPharm | Financial Buzz

“Buzz on the Street” Show: Mydecine Innovations Group (OTC: NLBIF) (CSE: MYCO) to Acquire NeuroPharm

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Mydecine Innovations Group to Acquire NeuroPharm Inc..”

Mydecine Innovations Group Inc. (OTC: NLBIF) (CSE: MYCO), is pleased to announce it has signed a non-binding Letter of Intent (“LOI”) dated June 9, 2020 to acquire NeuroPharm Inc., (“NeuroPharm”) a Canadian-based healthcare company working to deploy the power of nature’s medicine for the wellness of veterans, EMS and front line personnel in  North America and globally (the “Acquisition”).

Mydecine Innovations Group Inc. is the parent company operating innovative product divisions in the Naturally Sourced Therapies (NST) space. While controlling a variety of Psilocybin and hemp-derived CBD brands that design, manufacture, and distribute cutting edge products, Mydecine Innovations Group Inc. further enhances its portfolio with numerous cultivation properties, retail locations, and other land assets.

Depression and PTSD are serious psychiatric disorders which happen to share some similar symptoms. Either disorder might cause trouble sleeping, anger over little things, or a loss of interest in people or things. Sometimes, having both conditions is possible. As such, scientists are constantly working on how to better understand the intricacies of psychiatric disorders and on possible treatments as well. In recent years, views on psychedelic therapy have started to change. 2016 had been, in particular, a breakthrough year for psychedelic therapy. First, a study from the Beckley Foundation, in partnership with Imperial College London, found that all 12 patients showed some reduction in depression severity at 1 week that was sustained in the majority for 3 months, and according to standard criteria for determining remission (eg, a score of ≤9 on the BDI), eight (67%) of the 12 patients achieved complete remission at 1 week. Later that year, two U.S. university studies jointly published their findings of psilocybin effects on 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. According to the results, about 80% of participants continued to show clinically significant decreases in depressed mood and anxiety. 

Now, years later, new data continues to indicate that psychedelics could be used for legitimate medical purposes. In particular, this may also indicate that some legalization efforts will start to gain popularity as well. For example, back in 2019, Denver voters approved some of the nation’s first legal protections for psychedelic mushroom users, according to the Denver Post. Just like with cannabis and CBD products, legalization efforts will be spread to both the national and local levels. Over the past several years, the cannabis industry has achieved historic milestones and fully redefined itself, and it is large part thanks to various legislative victories in some of the largest states in the country, including California. Now, medical cannabis products are used for the treatment of various chronic conditions such as cancer, arthritis, and neurological conditions such as anxiety, depression, epilepsy, as well as Parkinson’s and Alzheimer’s disease. Such a wide scope of applications is also anticipated to further expand the target demographic of the market.

For more information, please visit: Mydecine Innovations Group Inc.

For more corporate news on Mydecine Innovations Group Inc., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For mydecine innovations group inc., video production, filming editing, news reporting, financial and corporate news dissemination, FinancialBuzz.com has been compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.